Document:

<PAGE>

                                                                    EXHIBIT 10.2

             CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    Certain portions, indicated by [*****], of this exhibit have been omitted
   pursuant to Rule 24b-2 of the Securities Act of 1934. The omitted materials
     have been filed separately with the Securities and Exchange Commission.

                                 STUDY AGREEMENT
                                     Between
                                Merck & Co., Inc.
                                       and
                       Cell and Molecular Technology, Inc.

This Agreement confirms the mutual understanding between Merck & Co., Inc., a
New Jersey corporation, having a place of business at One Merck Drive,
Whitehouse Station, NJ 08889-0100 ("Merck") and Cell and Molecular Technology,
Inc., having a place of business at 445 Marshall Street, Phillipsburg, NJ,
008865 ("CMTI").

1.    Definitions.

      "Affiliate" of Merck shall mean any entity (i) in which [*****] or more of
      the voting equity interests are now or hereafter owned or controlled,
      directly or indirectly, by Merck, (ii) which now or hereafter owns or
      controls, directly or indirectly, [*****] or more of the voting equity
      interests of Merck, or (iii) in which [*****] or more of the voting equity
      interests are now or hereafter owned or controlled, directly or
      indirectly, by an entity identified in the preceding clause (i) or (ii).

      "Agreement" shall mean this Study Agreement between Merck and CMTI.

      "Cause" is defined in Paragraph 13.

      "Final Report" is defined in Paragraph 7.

      "Inventions" shall mean any inventions or discoveries, whether or not
      patentable, made by employees and/or agents of CMTI (either solely or
      jointly with employees and/or agents of Merck) that arise from the Study.

      "Material" shall mean, [*****].

      "Merck Information" shall mean all information, data, Material and other
      items supplied by Merck or its Affiliates and all information and reports
      developed by CMTI as a result of the Study.

      "Study" shall mean the research described in the Work Plan, which is being
      conducted for the purpose set forth in Paragraph 2.

      "Term" is defined in Paragraph 4.

      "Work Plan" shall mean the Work Plan attached as Attachment A.

2.    Purpose. CMTI agrees to diligently perform the Study for cell line
      banking, characterization and phenotyping.

                                       29
<PAGE>

3.    Material. Merck shall supply, at no cost to CMTI, sufficient samples of
      the Material to carry out the Study in accordance with this Agreement. The
      Material is not to be used in humans. The Material is not to be reverse
      engineered for any purpose, including to identify structures or
      properties. It is understood that the Material is provided only for the
      performance of the Study and shall not be used for any other purpose, nor
      shall the Material or any derivatives, analogs, modifications or
      components thereof be transferred, delivered or disclosed to any third
      party without the advance written consent of Merck. Any unused Material
      and any derivatives, analogs, modifications or components thereof, shall
      be returned to Merck or otherwise disposed of in accordance with
      instructions from Merck promptly upon completion of the Study or as may be
      earlier required under Paragraph 13.

4.    Term. This Agreement shall be effective on the date of the last signature
      ("Effective Date"). The term of this Agreement shall expire on the one (1)
      year anniversary of the Effective Date, subject to early termination as
      provided in Paragraph 13 (the "Term").

5.    Amount.

      (a)   Merck shall pay CMTI a total of one million three hundred
            thirty-eight thousand one hundred thirty U.S. dollars ($1,
            338,130.00) for all costs and expenses associated with carrying out
            the Study [*****]. Payment shall be made as follows: Merck shall pay
            six hundred sixty nine thousand sixty-five U.S. dollars
            ($669,065.00), within [*****] days of receipt of an appropriate
            invoice from CMTI following the Effective Date and six hundred sixty
            nine thousand sixty-five U.S. dollars ($669,065.00) within [*****]
            days of receipt of the Final Report and an appropriate invoice from
            CMTI.

      (b)   Merck may request to have additional cell lines added to the Study.
            For each cell line to be analyzed in Part I of the Study, Merck
            shall pay CMTI [*****].

6.    Confidentiality. CMTI agrees to keep confidential and not to use, except
      for the purpose of conducting the Study, the Merck Information. These
      obligations of confidentiality and non-use shall continue during the Term
      of this Agreement and even after the Term expires. These obligations of
      confidentiality and non-use shall not apply to Merck Information which (i)
      is in the public domain by use and/or publication before its receipt from
      Merck or development under the Study, or thereafter enters the public
      domain through no fault of CMTI; (ii) was already in CMTI's possession
      prior to receipt from Merck or development under the Study, as evidenced
      by CMTI's written records; or (iii) is properly obtained by CMTI from a
      third party which has a valid right to disclose such information to the
      CMTI and is not under a confidentiality obligation to Merck.

7.    Reports; Use of Information. CMTI shall keep Merck informed of the
      progress of the Study by written reports on a bi-weekly basis as provided
      in the Work Plan, and will provide a complete written report of the Study
      results to Merck at the end of the Term ("Final Report"). Merck and its
      Affiliates shall have the unrestricted right to use and disclose all
      information in the Study reports and to use and disclose any technical
      information developed pursuant to this Agreement, for any and all purposes
      Merck and its Affiliates deem necessary or advisable in the ordinary
      course of business. At Merck's request, CMTI shall provide to Merck copies
      of all documentation and data relating to the Study or shall permit Merck
      to inspect and copy such documentation and data.

8.    Inventions.

      (a) CMTI shall promptly inform Merck in confidence of any Inventions
      relating to the Material. All Inventions shall be the sole and exclusive
      property of Merck. CMTI will, upon request by Merck, promptly execute any
      and all patent applications, assignments or other instruments which Merck
      deems are necessary or useful for the protection of any such Inventions,
      which may be filed or prepared at Merck's cost and expense.

      (b) CMTI represents and warrants that no governmental entity or other
      third party has or shall have any claim or right to the results of the
      Study or any Inventions.

9.    Publication. CMTI shall have no right hereunder to publish any of the
      Study results.

                                       30
<PAGE>

10.   Compliance With Law. CMTI shall conduct the Study in accordance with all
      applicable laws, rules and regulations, including, without limitation, all
      current governmental regulatory requirements concerning Good Laboratory
      Practices. CMTI will notify Merck in writing of any deviations from
      applicable regulatory or legal requirements. CMTI hereby certifies that it
      will not and has not employed or otherwise used in any capacity the
      services of any person debarred under Section 21 USC 335a in performing
      any services hereunder.

11.   Use of Human Materials. If any human cell lines, tissue, human clinical
      isolates or similar human-derived materials ("Human Materials") have been
      or are to be collected and/or used in the Study, CMTI represents and
      warrants (i) that it has complied, or shall comply, with all applicable
      laws, guidelines and regulations relating to the collection and/or use of
      the Human Materials and (ii) that it has obtained, or shall obtain, all
      necessary approvals and appropriate informed consents, in writing, for the
      collection and/or use of such Human Materials. CMTI shall provide
      documentation of such approvals and consents upon Merck's request. CMTI
      further represents and warrants that such Human Materials may be used as
      contemplated in this Agreement without any obligations to the individuals
      or entities ("Providers") who contributed the Human Materials, including,
      without limitation, any obligations of compensation to such Providers or
      any other third party for the intellectual property associated with, or
      commercial use of, the Human Materials for any purposes.

12.   Liability. Merck assumes no responsibility and shall have no liability for
      the nature, conduct or results of any research, testing or other work
      performed hereunder. CMTI UNDERSTANDS THAT THE MATERIAL IS SUPPLIED "AS
      IS" AND IS PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
      PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. CMTI
      ACKNOWLEDGES THAT THE MATERIAL IS EXPERIMENTAL IN NATURE AND MAY HAVE
      UNKNOWN HAZARDOUS CHARACTERISTICS, THAT THEY ARE AWARE OF THE RISKS OF
      WORKING WITH EXPERIMENTAL MATERIALS AND THAT THEY WILL STRICTLY ADHERE TO
      PROPER LABORATORY PROCEDURES FOR HANDLING CHEMICALS WITH UNKNOWN HAZARDS.
      THE MATERIAL WILL NOT BE USED IN HUMANS.

13.   Termination. (a) Merck may terminate this Agreement at any time, with or
      without Cause, effective upon [*****] days' written notice to CMTI. In the
      event of a termination of this Agreement without Cause, Merck shall
      reimburse CMTI for the pro-rata costs incurred in performance of the Study
      and for any non-cancelable commitments made, up to the date of
      termination; provided, however, that in no case will reimbursement under
      this Agreement exceed the amount specified in Paragraph 5. If this
      Agreement is terminated for Cause, then in addition to any other remedies
      available to Merck, no such reimbursement shall be paid by Merck to CMTI.
      For the purposes of the foregoing, "Cause" shall mean the breach by CMTI
      of any of its representations or warranties under this Agreement, or the
      failure of CMTI to comply with any of its obligations hereunder.

      (b) Upon termination of this Agreement, or at any other time that Merck
      may request, CMTI agrees to return all Merck Information, and all
      documents generated by CMTI in connection with the Study to Merck, except
      CMTI may retain one copy in a secure location solely for recordkeeping
      purposes.

14.   Survival. The provisions of Paragraphs 3(b) (other than Merck's
      obligations to supply the Material), 6, 7, 8, 9, 11, 12, 13, 14, 15, 16,
      17, 18 and 20 and all definitions relating to the foregoing, shall survive
      termination or expiration of this Agreement.

15.   Notices. Any notices required or provided by the terms of this Agreement
      shall be in writing, addressed in accordance with this Paragraph, and
      shall be delivered personally or sent by certified or registered mail,
      return receipt requested, postage prepaid or by nationally-recognized
      express courier services providing evidence of delivery. The effective
      date of any notice shall be the date of first receipt by the receiving
      party. Notices shall be sent to the address/addressee given below or to
      such other address/addressee as the party to whom notice is to be given
      may have provided to the other party in writing in accordance with this
      provision.

                                       31
<PAGE>

         If to Merck:                       [*****]

         With a copy to:                    [*****]
                                            Merck & Co., Inc.
                                            P.O. Box 100
                                            One Merck Drive
                                            Whitehouse Station, NJ
                                            08889-0100

         If to CMTI:                        [*****]
                                            Cell and Molecular Technology, Inc.
                                            445 Marshall Street,
                                            Phillipsburg, NJ, 008865

16.   Governing Law. This Agreement shall be construed in accordance with the
      laws of the State of New Jersey, and the patent laws of the United States,
      without reference to provisions of conflicts of laws.

17.   Entire Agreement. This Agreement, together with any Attachments attached
      hereto and specifically referenced herein, constitutes the entire
      agreement between the parties with respect to the Study and supersedes and
      replaces any and all previous arrangements and understandings, whether
      oral or written, between the parties with respect to the Study . Any
      amendment or modification to this Agreement shall be of no effect unless
      made in writing signed by an authorized representative of each party.

18.   Publicity/Use of Names. No disclosure of the existence, or the terms, of
      this Agreement may be made by either party, and no party shall use the
      name, trademark, trade name or logo of the other party or its employees in
      any publicity, promotion, news release or disclosure relating to this
      Agreement or its subject matter, without the prior express written
      permission of the other party, except as may be required by law.

19.   Assignment. CMTI may not assign its rights or obligations under this
      Agreement without the prior written consent of Merck. Any such purported
      assignment shall be void.

20.   Severability. The provisions of this Agreement are severable, and if any
      provisions hereof shall be determined to be invalid or unenforceable by a
      court of competent jurisdiction, the remaining provisions shall continue
      in full force and effect.

            IN WITNESS WHEREOF, the parties have caused this Agreement to be
      executed by their duly authorized representatives, effective as of the
      date of the last signature set forth below.

MERCK & CO., INC.                            CELL & MOLECULAR TECHNOLOGY , INC.

BY: /s/  [*****]                             BY: /s/ Thomas J. Livelli

TITLE: [*****]                               TITLE: Chief Executive Officer

DATE: 8/18/04                                DATE: 8/18/04

                                       32
<PAGE>

                                  ATTACHMENT A
                                    WORK PLAN

BACKGROUND

[*****]

PROPOSAL

[*****]

PART #1

[*****]

PART #2

[*****]

                                       33<PAGE>

                                                                    EXHIBIT 10.3

                             SENTIGEN HOLDING CORP.
                               580 MARSHALL STREET
                             PHILLIPSBURG, NJ 08865

                                                                   July 19, 2004

Mr. Erik R. Lundh

Dear Erik:

This letter agreement will confirm the terms and conditions of our arrangement
wherein you are being retained by Sentigen Holding Corp. ("Sentigen") as a
consultant.

      Duties. Sentigen hereby retains you as an independent contractor to
perform non-exclusive consulting services related to the business development
activities of Sentigen and its subsidiary, Sentigen Biosciences, Inc. ("Sentigen
Biosciences") and you hereby accept such retention. You shall report to Joseph
K. Pagano, Chief Executive Officer of Sentigen, and will perform such functions
as he may from time to time reasonably request. You will devote such time and
energy to Sentigen as is reasonably necessary to fulfill your obligations
hereunder.

      Term. You will be retained for a period commencing on the date hereof
until such time as you or Sentigen give the other party thirty days written
notice of the termination of this agreement.

      Compensation. As compensation for your consulting services hereunder, you
shall be paid a per diem rate of $800 per day for each full working day you
provide services hereunder. You will submit statements on a weekly basis
indicating the number of days worked during the prior week. You will be paid
biweekly.

      Expenses. Sentigen agrees to reimburse you for any reasonable
out-of-pocket expenses (in accordance with normal Sentigen policy) incurred by
you in connection with the services rendered hereunder upon presentment of
vouchers for those expenses. Major travel and expense expenditures shall be
precleared by Sentigen and incurred in accordance with normal Sentigen travel
and expense policies.

      Stock Options. Reference is made to the option to purchase 50,000 shares
of Common Stock of the Company at a price per share of $4.75 granted to you on
the 4th day of September, 2003 (the "Option") pursuant to the Company's
Performance Equity Plan (the "Plan"). For a term of thirteen months from the
date hereof, the Option shall be exercisable with respect to 10,000 shares of
Common Stock. Subject to your remaining in continuous service as a consultant to
the Company, the remaining portion of the Option shall become exercisable with
respect to an additional 833 shares of Common Stock on the first day of each
month commencing October 1, 2004, which remaining portion shall immediately
terminate and cease to be exercisable twelve months after the termination of
this agreement. You hereby acknowledge that the Option will no longer qualify as
an "incentive stock option" under Section 422 of the Internal Revenue Code of
1986, as amended. The Option shall continue to be subject to the terms and
conditions of the Plan and, except as modified herein, the terms and conditions
of that certain option agreement dated as of the 4th day of September, 2003
evidencing the Option (the "Option Agreement"). Without limiting the foregoing,
you hereby acknowledge that the provisions of Sections 2, 5 and 6 of the Option
Agreement shall cease to apply.

      Health Insurance. You are eligible for continuation medical coverage
pursuant to COBRA. Upon electing such continuation coverage, Sentigen shall pay
the insurance premiums on your behalf for the earlier of the term of this
agreement or your obtaining alternative employment that provides medical
benefits to you.

      Other Agreements. Reference is made to Sections 8, 9, 10 and 14 of your
Employment Agreement dated September 2, 2003 relating to Confidential
Information, Assignment of Inventions and Original Works, Non-Competition. and
Remedies. You agree that the provisions of such sections shall be incorporated
herein and shall survive the termination of your Employment Agreement except
that all references to your "employ" or

                                       34
<PAGE>

"employment" with Sentigen or the "Employment Term" shall also relate to your
consultancy and the term of your consultancy, respectively, hereunder.

      Governing Law. This Agreement shall be governed by the laws of New York
without regard to conflicts of laws.

      Successors and Assigns, Amendments. This Agreement shall be binding on and
inure to the benefit of the parties hereto and their respective successors and
assigns. This Agreement may not be modified or amended except in writing signed
by the parties hereto.

      Severability. If any provision of this Agreement for any reason shall be
held to be illegal, invalid or unenforceable, such provision shall not effect
any other provision of this Agreement, and this Agreement shall be construed as
if such illegal, invalid or unenforceable provision had never been included
herein. Please indicate your agreement with this letter agreement by signing
below.

                                           Very truly yours,

                                           SENTIGEN HOLDING CORP.

                                           By: /s/ Joseph K. Pagano
                                              -----------------------------
                                              Name: Joseph K. Pagano
                                              Title: Chairman of the Board

Accepted and Agreed To:

/s/ Erik R. Lundh
-----------------
Erik R. Lundh

                                       35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]